Saturday Evening Post Interviews Dr. Andrew Stoll
The following was excerpted from “Battling The Blues: Ongoing research shows that omega-3 fatty acids help treat depression”:
Post: Do omega-3 fatty acids continue to demonstrate mood-stabilizing benefits?
Dr. Stoll: No one has replicated the findings of our original study as yet. The real story now is that there are now numerous positive studies on the benefits of omega-3 in unipolar depression, schizophrenia, borderline personality disorder, ADHD, and Huntington’s disease.
It seems that many disorders respond to omega-3s. Three of the four studies in depression used EPA, or EPA plus DHA, and they worked. The fourth study used pure DHA–important for developing babies, pregnant women, and nursing mothers–and it failed. People hold onto stores of DHA for a long time, so you don’t need to replenish levels as often as with EPA, which is turned over constantly, by conversion into eicosanoid hormones.
Post: Does EPA have anti-inflammatory properties?
Dr. Stoll: Exactly. The anti-inflammatory action of omega-3s has been definitively shown to help prevent heart attacks, in part by reducing atherosclerosis (hardening of the arteries). Omega-3s also appear to help cut down on the need for medications to treat rheumatoid arthritis, ulcerative colitis, Crohn’s disease, and a number of other medical conditions. Omega-3s may also work in osteoarthritis. Research on omega-3s is exploding–and not just in psychiatry.
Post: Are you continuing your research into the relationship between fats and mental health, particularly omega-3 fish oils in bipolar disorder?
Dr. Stoll: Yes. We published the results of our first bipolar study, and the results were very promising. We went out on a limb to do this study with no funding and with colleagues sometimes ridiculing us. But the study was logical and rational, and patients, as well as informed and open-minded physicians, liked the approach. We tried it randomly and it worked. The same pathways are activated during bipolar disorder and depression, so EPA may perform the anti-inflammatory action.
Post: Do your patients, who were part of the original study, continue to take omega-3 and experience relief from their symptoms?
Dr. Stoll: I still see some of these people. All continue to take omega-3 supplements. In my practice, I am in favor of it, so I advise people to take it–if not for the psychiatric benefits, then for the general health benefits.
Post: Is there a downside to supplementing with omega-3?
Dr. Stoll: There isn’t. Some people may experience GI distress if they take a large amount of a low-quality supplement. But the highest good-quality fish oil is not rancid and has little or no taste and has no side effects. Another issue that people worry about is bleeding, because EPA inhibits platelet aggregation. But we scoured the scientific literature, and there has never been a documented case of bleeding due to omega-3 fatty acids.
We recently reviewed about 18,000 people who participated in clinical trials with omega-3s, largely in cardiology studies, and we couldn’t find one instance of bleeding in any of the trials. There was no bleeding, even if used in IVs prescribed before and during cardiac surgery. I think this perception is a myth because omega-3s don’t inhibit the platelets as strongly as aspirin–perhaps 60 to 70 percent as much as aspirin–and unlike aspirin, the effect is reversible.
Post: When a patient is on blood thinners, such as coumadin, should they exercise caution when supplementing with omega-3?
Dr. Stoll: In that situation, I usually recommend a lower dose, not exceeding one or two grams of EPA per day. At this dosage, there should be no effect on the action of coumadin. The unanswered question is, together are they providing too much anticoagulation?
Nonetheless, there may be some minute risk of a negative interaction with anticoagulants, such as warfarin (coumadin), high-dose aspirin, or ibuprofen-like medications, based on animal data and anecdotal reports in humans.
However, large-scale controlled clinical trials with patients receiving omega-3 fatty acid supplements with either aspirin or warfarin observed no cases of bleeding even after one year of the combined treatments. It would be a shame if cardiac patients or their physicians avoided the use of omega-3 supplements out of fear. I am thoroughly convinced that the dramatic and lifesaving cardiac actions of omega-3s far outweigh the very small or nonexistent risk of bleeding.
Post: What dosage do you recommend for patients with bipolar and/or depression?
Dr. Stoll: Our omega-3-fatty-acids-in-bipolar study was the first controlled study in psychiatry. We really had no way of knowing what the minimum effective dosage as, so we decided to use a moderately high dosage that had been successfully used in omega-3 studies of rheumatoid arthritis and other medical disorders. This dosage was about 10 grams per day (6.5 grams of EPA and 3.5 grams of DHA daily). Most of the newer omega-3 studies in major depression used a very low dosage of pure EPA added to partially effective or noneffective antidepressants. For example, in one small study, Dr. Malcolm Peet and colleagues from England compared one gram a day of EPA to two grams a day of EPA, and up to four grams of EPA per day. One gram of EPA did the best by far. The most recent depression study, done by a group from Taiwan, was another unipolar study where they added omega-3 to an antidepressant regimen that was not working. They used the same exact formulation that we did–nearly 10 grams of EPA plus DHA in about a 3:2 ratio–with good results.
So, the question of optimal dosage remains unanswered. Practically, I start patients on one gram of EPA per day, and go up on the dosage gradually until an effect is seen on a person’s mood. I usually do not have to exceed six grams of EPA per day. The amount of omega-3 in a supplement may be calculated from the side of the bottle.
It is important to know that the amount of active ingredients in supplements is listed on the label by serving size, not necessarily by how much of an ingredient or compound is in one capsule. Companies can make the serving size one, two, three, or a hundred capsules–as big or small as they want.
To determine omega-3 content, simply take the amount of EPA or EPA plus DHA per serving, as listed on the label, and divide it by the serving size to determine how much omega-3 is in each capsule. That’s not understood well by many people. It is important that people read labels carefully. They get fooled.
The FDA requires that supplement manufacturers list the ingredients or nutrients by serving size. But the company can put in any serving size they want, so it may look like there is a lot of EPA, for example, in a product, but the serving size may be 10 capsules. Consumers should be sure to divide whatever value is in the column for the amount of EPA by the number of capsules in a serving, and read labels carefully.
Post: What dose of omega-3 do you recommend and find most effective?
Dr. Stoll: I will distinguish the doses. I usually start everyone on one gram of EPA per day. I prefer to have a little bit of DHA in the formula. They should be at least in a 3:2 or 2:1 EPA to DHA ratio. If one gram doesn’t help after one to two weeks, I will raise the dosage to two grams a day of EPA. I definitely use lower doses than I used to, based on the depression data. Occasionally, someone will call or e-mail me with an anecdote that they didn’t respond until they were taking 10 grams a day–the original dose in our study. Hopefully, we will resolve that issue in the next few years.
Post: When consumers are looking at supplements, what is the ideal ratio of EPA to DHA that they should look for?
Dr. Stoll: This remains an unresolved issue, but I like a 7:1 ratio of EPA to DHA. That high ratio delivers plenty of EPA–the presumed active ingredient–and also rovides an adequate amount of DHA. More DHA is required during pregnancy or while nursing to replenish stores. Most adults and children seem to have adequate or nearly adequate stores of DHA in their brains. Believe it or not, these DHA stores in the membranes of brain cells date back to a person’s fetal life and is provided by their mothers. DHA turns over very slowly, so you don’t need much to get by. In contrast, EPA is turned over very rapidly, as it is used for eicosanoid synthesis. For this reason, we think people are also much more depleted in EPA than DHA. Ω
SOURCE: Saturday Evening Post, May/June 2005, by Patrick Perry.
[full article]